MiMedx Group Inc. (MDXG)
NASDAQ:MDXG
Want to see MDXG full AI Analyst Report?
Top Page
MiMedx Group
(NASDAQ:MDXG)
Select Model
Select Model
Rating:72Outperform
Price Target:
$4.00
▲(16.96% Upside)
Action:Upgraded
Date:06/17/26
The score is driven primarily by improved fundamentals—strong margins, solid cash generation, and a very low-leverage balance sheet—tempered by a TTM revenue decline and some margin softening. Technicals remain mixed with the stock still below longer-term moving averages, while valuation is reasonable (P/E ~17.9) but lacks dividend support. Corporate events add both cost-savings upside and near-term execution risk from restructuring.
Positive Factors
High gross margins
Sustained gross margins near 81–83% indicate strong product-level economics and pricing power for placental allografts. This structural margin advantage supports durable profitability, funds reinvestment into sales and R&D, and cushions operating margins against moderate cost increases over the next 2–6 months.
Negative Factors
TTM revenue decline
A nearly 7% TTM revenue decline signals weakening demand or disrupted utilization in core wound-care markets. Persistent top-line contraction can erode operating leverage, pressure margins, and constrain reinvestment capacity if not reversed by stabilization in reimbursement or volume recovery over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins near 81–83% indicate strong product-level economics and pricing power for placental allografts. This structural margin advantage supports durable profitability, funds reinvestment into sales and R&D, and cushions operating margins against moderate cost increases over the next 2–6 months.
Read all positive factors
MiMedx Group (MDXG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$585.36M
Dividend YieldN/A
Average Volume (3M)1.40M
Price to Earnings (P/E)19.2
Beta (1Y)0.46
Revenue Growth10.51%
EPS Growth-23.96%
CountryUS
Employees837
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.21
Shares Outstanding148,945,720
10 Day Avg. Volume1,193,400
30 Day Avg. Volume1,399,944
Financial Highlights & Ratios
PEG Ratio1.49
Price to Book (P/B)3.90
Price to Sales (P/S)2.39
P/FCF Ratio13.71
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue1.02
Enterprise Value/Gross Profit1.25
Enterprise Value/Ebitda6.91
Forecast
1Y Price Target
$6.25Price Target Upside82.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.01
Revenue Forecast (FY)$268.69M
MiMedx Group Business Overview & Revenue Model
Company Description
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucia...
How the Company Makes Money
MiMedx makes money primarily by selling placental tissue-derived allograft products to healthcare providers and healthcare facilities for use in clinical settings (e.g., wound care and surgical recovery). Revenue is generated when its products are...
MiMedx Group Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Neutral
The call highlights a strong 2025 with record revenue, margin expansion and a fortified balance sheet, plus clear growth momentum and product/clinical progress in the Surgical segment. However, substantial near-term headwinds in the Wound Care market — driven by Medicare reimbursement changes, pricing disruption, prior-authorization delays and uncertainty around market sizing — lead management to guide to a lower revenue and margin profile for 2026. The company emphasizes confidence in its long-term positioning and expects recovery and above-market growth by 2027, but acknowledges a noisy transition year ahead.Positive Updates
Record Full-Year Financial Performance
Net sales of $419 million in 2025, representing 20% year-over-year growth; full-year adjusted EBITDA of nearly $106 million (approximately 25% adjusted EBITDA margin); GAAP net income of $49 million.
Negative Updates
Wound Care Reimbursement Disruption
Medicare recalibration (price cap $127 per square centimeter) and abandonment of LCD implementation have disrupted the Wound market; implementation of WISeR prior authorization in some states has slowed claims processing and reduced near-term volume.
Read all updates
Q4-2025 Updates
Positive
Negative
Record Full-Year Financial Performance
Net sales of $419 million in 2025, representing 20% year-over-year growth; full-year adjusted EBITDA of nearly $106 million (approximately 25% adjusted EBITDA margin); GAAP net income of $49 million.
Read all positive updates
Company Guidance
The company guided 2026 revenue to $340–$360 million, with Q1 expected to be the weakest quarter and “substantial” sequential increases each quarter as the market resets, and full‑year adjusted EBITDA targeted in the mid‑ to high‑teens (percent). For 2026 they expect gross margin in the mid‑ to upper‑70s, sales & marketing spending around ~50% of net sales, GAAP G&A and R&D to be flat in absolute dollars versus 2025, and a long‑term non‑GAAP effective tax rate of ~25%. Management reiterated a longer‑term view of returning to double‑digit, above‑market top‑line growth and a mid‑20s EBITDA margin by 2027 with revenue back over $400M, noted year‑end 2025 net cash of $148M (FY2025: $419M revenue and ~ $106M adjusted EBITDA), and that the Board authorized up to $100M in share repurchases over the next two years.MiMedx Group Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
88
Very Positive
Cash Flow
79
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 389.42M | 418.63M | 348.88M | 321.48M | 267.84M | 242.02M |
| Gross Profit | 315.59M | 345.62M | 288.81M | 266.84M | 219.53M | 202.39M |
| EBITDA | 57.26M | 82.93M | 65.35M | 40.52M | -10.69M | -1.89M |
| Net Income | 30.70M | 48.58M | 42.42M | 67.44M | -30.20M | -12.30M |
Balance Sheet | ||||||
| Total Assets | 308.68M | 342.65M | 263.92M | 239.05M | 171.43M | 187.93M |
| Cash, Cash Equivalents and Short-Term Investments | 159.77M | 166.12M | 104.42M | 82.00M | 65.95M | 87.08M |
| Total Debt | 17.59M | 22.53M | 24.84M | 48.10M | 52.47M | 53.29M |
| Total Liabilities | 65.74M | 86.11M | 70.81M | 96.33M | 96.92M | 95.35M |
| Stockholders Equity | 242.94M | 256.55M | 193.11M | 142.72M | 74.51M | 92.58M |
Cash Flow | ||||||
| Free Cash Flow | 65.50M | 72.97M | 64.52M | 24.79M | -19.41M | -5.20M |
| Operating Cash Flow | 70.58M | 74.00M | 66.20M | 26.77M | -17.89M | -1.98M |
| Investing Cash Flow | -12.12M | -6.89M | -9.58M | -2.15M | -2.66M | -3.40M |
| Financing Cash Flow | -5.12M | -5.41M | -34.20M | -8.57M | -580.00K | -3.35M |
MiMedx Group Technical Analysis
Neutral
3.42
Price Trends
3.59
Positive
4.07
Negative
5.40
Negative
Market Momentum
0.04
Negative
63.53
Neutral
83.23
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Neutral. The current price of 3.42 is below the 20-day moving average (MA) of 3.70, below the 50-day MA of 3.59, and below the 200-day MA of 5.40, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 63.53 is Neutral, neither overbought nor oversold. The STOCH value of 83.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MDXG.
MiMedx Group Risk Analysis
MiMedx Group disclosed 84 risk factors in its most recent earnings report. MiMedx Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MiMedx Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $585.36M | 19.16 | 12.86% | ― | 10.51% | -23.96% | |
56 Neutral | $938.23M | 68.10 | 4.75% | ― | 15.66% | ― | |
52 Neutral | $1.49B | ― | -366.49% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $986.52M | -6.62 | -35.33% | ― | ― | 23.91% | |
46 Neutral | $1.57B | -10.34 | -36.63% | ― | ― | ― |
* Healthcare Sector Average
MDXG
MiMedx Group
3.93
-2.18
-35.68%
ORIC
Oric Pharmaceuticals
9.53
-0.62
-6.11%
PHAR
Pharming Group
13.34
2.65
24.79%
ATAI
Atai Beckley N.V.
5.29
3.10
141.55%
MAZE
Maze Therapeutics, Inc.
28.43
16.16
131.70%
MiMedx Group Corporate Events
Executive/Board ChangesShareholder Meetings
MiMedx Shareholders Back Board, Pay and Bylaw Changes
Positive
Jun 16, 2026
On June 10, 2026, MiMedx Group’s board approved an amendment to its Amended Restated Bylaws, raising the cap on the number of public-company boards its chief executive officer may serve on to three, a change that could broaden the CEO’...
Business Operations and StrategyExecutive/Board Changes
MiMedx launches restructuring to cut costs, refocus growth
Negative
Apr 16, 2026
On April 14, 2026, MiMedx initiated a restructuring and cost reduction program designed to prioritize growth areas, streamline operations and materially lower operating expenses, including eliminating the Chief Operating Officer role held by Ricci...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.